AZN vs MCK
AZN: AstraZeneca is a global biopharmaceutical leader driving innovation in oncology, rare diseases, and specialized biopharmaceuticals to transform patient outcomes. MCK: McKesson is a healthcare services giant that orchestrates the entire pharmaceutical and medical supply chain—from drug distribution and specialty oncology care to technology platforms that connect patients, pharmacies, and providers.
Side-by-side fundamentals
| Metric | AZN | MCK | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $169.64 | $856.19 | |
| Market cap as of 2026-08-03 | $197.3B | $102.9B | |
| P/E as of 2026-08-03 | 25.47 | 22.27 | MCK lower |
| PEG as of 2026-08-03 | 2.64 | 1.70 | MCK lower |
| Net margin as of 2026-08-03 | +17.0% | +1.2% | AZN higher |
| Gross margin as of 2026-08-03 | +81.3% | +3.6% | AZN higher |
| Operating margin as of 2026-08-03 | +22.8% | +1.5% | AZN higher |
| ROE as of 2026-08-03 | +21.7% | +39.4% | MCK higher |
| ROA as of 2026-08-03 | +9.1% | +5.7% | AZN higher |
| Debt / equity as of 2026-08-03 | 0.64 | 1.29 | AZN lower |
| Revenue growth (YoY) as of 2026-08-03 | +8.6% | +12.4% | MCK higher |
| Revenue CAGR (3y) SEC XBRL | +9.8% | +13.4% | MCK higher |
| Dividend yield as of 2026-08-03 | +1.9% | +0.4% | AZN higher |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-08-03 | 1.34 | 0.02 | |
| 1-year return as of 2026-07-27 close | +16.7% | +23.5% | MCK higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.